Regeneration Technologies, Tutogen Medical Announce New Name for Proposed Merged Companyhttp://www.tutogen.com

  
    
  
  
    
      Regeneration Technologies, Inc. (RTI) (Nasdaq:RTIX) and Tutogen Medical, 
      Inc. (AMEX:TTG) today announced that with the proposed merger of the two 
      companies, they will ask RTI shareholders to approve a new company name – 
      RTI Biologics, Inc. The stock will continue to trade on the Nasdaq 
      Global Market under the symbol RTIX.
    
    
      The newly combined and newly named company of RTI Biologics will be 
      positioned as a leader in biologics, a growing area in the healthcare 
      industry and a key strength for both companies.
    
    
      “Our new company name is centered around ‘Biologics,’ 
      which can include a wide array of biological solutions. These are areas 
      that represent strong growth and great promise in healthcare,” 
      said Brian K. Hutchison, RTI’s chairman, 
      president and CEO. “We feel it is important to 
      begin this new endeavor with a fresh brand that better represents the 
      strengths of both RTI and Tutogen.”
    
    
      While the company name will become RTI Biologics, the combined company 
      will continue to use and leverage the strengths of both the BioCleanse® 
      and Tutoplast® brand names, which are 
      well-known throughout the medical community as the standards for 
      sterilization, safety and quality of orthopedic and membrane tissues, 
      respectively.
    
    
      A special meeting of the stockholders of RTI, to consider and vote upon 
      the transactions contemplated by the proposed merger with Tutogen, has 
      been scheduled for Feb. 27, 2008 at 9:00 a.m. Eastern Time, at RTI’s 
      headquarters at 11620 Research Circle, Alachua, Fla. RTI stockholders of 
      record as of the close of business on Jan. 16, 2008 will be entitled to 
      vote at the special meeting.
    
    
      A special meeting of the stockholders of Tutogen, to consider and vote 
      upon the transactions contemplated by the proposed merger with RTI, has 
      been scheduled for Feb. 27, 2008 at 9:00 a.m. Eastern Time, at Tutogen’s 
      headquarters at 13709 Progress Blvd., Alachua, Fla. Tutogen stockholders 
      of record as of the close of business on Jan. 22, 2008 will be entitled 
      to vote at the special meeting.
    
    
      The companies announced on Nov. 13, 2007 a definitive agreement to 
      combine the two companies in a tax-free, stock-for-stock exchange. Under 
      the terms of the merger agreement, Tutogen shareholders will receive 
      1.22 shares of newly issued RTI common stock in exchange for each share 
      of Tutogen common stock they own. Upon completion of the merger, RTI 
      stockholders will own approximately 55 percent of the combined company 
      and Tutogen stockholders will own 45 percent of the company, on a 
      diluted basis.
    
    
      About Regeneration Technologies, Inc.
    
    
      RTI processes allograft and xenograft tissue into shaped implants for 
      use in orthopedic and other surgeries with a commitment to science, 
      safety and innovation.
    
    
      RTI also holds the patents on BioCleanse®, a 
      proven tissue sterilization process validated to eliminate viruses, 
      bacteria, fungi and spores from tissue without impacting the structural 
      or biomechanical integrity of the tissue. The company has distributed 
      more than half a million allograft implants sterilized with the 
      BioCleanse process with zero incidence of infection. RTI is accredited 
      by the American Association of Tissue Banks.
    
    
      About Tutogen Medical, Inc.
    
    
      Tutogen Medical, Inc. manufactures sterile biological implant products 
      made from human (allograft) and animal (xenograft) tissue. Tutogen 
      utilizes its proprietary Tutoplast® Process 
      of tissue preservation and viral inactivation to manufacture and deliver 
      sterile bio-implants used in spinal/trauma, urology, dental, 
      ophthalmology, and general surgery procedures. Tutogen’s 
      Tutoplast products are sold and distributed worldwide by Zimmer Spine 
      and Zimmer Dental (subsidiaries of Zimmer Holdings, Inc.), Davol Inc. (a 
      subsidiary of C.R. Bard Inc.), the Mentor Corporation (Mentor), 
      Coloplast Corporation, IOP, Inc. and through independent distributors 
      internationally. For more information, visit Tutogen’s 
      web site at http://www.tutogen.com.
    
    
      Forward-Looking Statements
    
    
      This communication contains "forward-looking statements" within the 
      meaning of the Private Securities Litigation Reform Act of 1995. Such 
      statements include but are not limited to statements about the expected 
      benefits of the business combination involving Regeneration 
      Technologies, Inc. and Tutogen Medical, Inc., including potential 
      synergies and cost savings, future financial and operating results, and 
      the combined company's plans and objectives. In addition, except for 
      historical information, any statements made in this communication about 
      anticipated financial results, growth rates, new product introductions, 
      future operational improvements and results, regulatory approvals or 
      changes to agreements with distributors also are forward-looking 
      statements. Forward-looking statements are subject to risks and 
      uncertainties, including the ability of Regeneration Technologies and 
      Tutogen to integrate their businesses successfully and to realize the 
      expected synergies and cost savings from the merger and the risks 
      described in public filings by Regeneration Technologies and Tutogen on 
      file with the Securities and Exchange Commission. Actual results may 
      differ materially from anticipated results reflected in these 
      forward-looking statements. Copies of Regeneration Technologies' SEC 
      filings may be obtained by contacting Regeneration Technologies or the 
      SEC or by visiting Regeneration Technologies' Web site at www.rtix.com 
      or the SEC's Web site at www.sec.gov. 
      Copies of Tutogen's SEC filings may be obtained by contacting Tutogen or 
      the SEC or by visiting Tutogen's Web site at www.tutogen.com 
      or the SEC's Web site at www.sec.gov.
    
    
      The proposed merger will be submitted to the respective 
      stockholders of Regeneration Technologies and Tutogen for their 
      consideration, and Regeneration Technologies and Tutogen have filed a 
      registration statement, a joint proxy statement/prospectus and other 
      relevant documents concerning the proposed transaction with the SEC. 
      Shareholders are urged to read the registration statement and the 
      joint proxy statement/prospectus regarding the proposed merger and any 
      other relevant documents filed with the SEC, as well as any amendments 
      or supplements to those documents, because they will contain important 
      information. You can obtain a free copy of the joint proxy 
      statement/prospectus, as well as other filings containing information 
      about Regeneration Technologies and Tutogen, at the SEC's Internet site (http://www.sec.gov). 
      You will also be able to obtain these documents, free of charge, 
      at RTI’s website (http://www.rtix.com) 
      or Tutogen’s website (http://www.tutogen.com). 
      Copies of the joint proxy statement/prospectus and the SEC filings 
      that are incorporated by reference in the joint proxy 
      statement/prospectus can also be obtained, without charge, by directing 
      a request to Thomas F. Rose, Vice President and CFO, Regeneration 
      Technologies Inc., PO Box 2650, Alachua, FL 32616 or to L. Robert 
      Johnston, Jr., CFO, Tutogen Medical Inc., 13709 Progress Blvd., Box 19, 
      Alachua, FL 32615.
    
    
      Regeneration Technologies and Tutogen, and their respective 
      directors and executive officers, may be deemed to be participants in 
      the solicitation of proxies from the stockholders of Regeneration 
      Technologies and Tutogen in connection with the proposed merger. Information 
      about the directors and executive officers of Regeneration Technologies 
      and their ownership of Regeneration Technologies common stock is set 
      forth in the proxy statement, dated March 30, 2007, for Regeneration 
      Technologies’ annual meeting of stockholders, 
      as filed with the SEC on a Schedule 14A. Information about 
      the directors and executive officers of Tutogen and their ownership of 
      Tutogen common stock is set forth in the proxy statement, dated Feb. 5, 
      2007, for Tutogen's annual meeting of stockholders, as filed with the 
      SEC on a Schedule 14A. Additional information regarding 
      the interests of those participants and other persons who may be deemed 
      participants in the merger may be obtained by reading the joint proxy 
      statement/prospectus regarding the proposed merger. You 
      may obtain free copies of these documents as described in the preceding 
      paragraph.
    
    
      This communication shall not constitute an offer to sell or the 
      solicitation of an offer to buy securities, nor shall there be any sale 
      of securities in any jurisdiction in which such offer, solicitation or 
      sale would be unlawful prior to registration or qualification under the 
      securities laws of any such jurisdiction. No offering of 
      securities shall be made except by means of a prospectus meeting the 
      requirements of Section 10 of the Securities Act of 1933, as amended.